North America Colorectal Cancer Market to 2027

North America Colorectal Cancer Market to 2027 - Regional Analysis and Forecasts by Modality (Diagnosis Type, Therapy Type, Imaging Type); End User (Hospitals, Diagnostic and Research Laboratories), and Country

Report Code : TIPRE00009241 | Region : North America | Industry : Pharmaceuticals | Published Date : 23/Sep/2022

The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.

North America Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

North America Colorectal Cancer Market Segmentation

The North America colorectal cancer market is segmented into modality, end user, and country. Based on modality, the North America colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the North America colorectal cancer market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the North America colorectal cancer market.

At 3.4% CAGR, the North America Colorectal Cancer Market is speculated to be worth US$ 11,198.11 Million by 2028, says The Insight Partners

According to The Insight Partners’ research, the North America colorectal cancer market was valued at US$ 8,559.27 million in 2022 and is expected to reach US$ 11,198.11 million by 2028, registering an annual growth rate of 3.4% from 2022 to 2028. Rising prevalence of colorectal cancer and various new product launches are the critical factors attributed to the market expansion.

The market for colorectal cancer drugs is ascribed to frequent diagnostic tests and drug launches. Most of the major market players are involved in manufacturing a wide range of drugs and diagnostic tests that help in reducing the burden of colorectal cancer. Several companies are focused on the development of new diagnostic tests that will help in the accurate detection of colorectal cancer. For instance, in June 2018, CellMax Life, one of the leading cancer diagnostics companies, launched Zenith, a US clinical study for CellMax Life's unique expertise in circulating tumor cells (CTC) intended to diagnose colorectal and other types of cancer. Thus, the constant developments and new product launches in colorectal cancer diagnostics and therapeutics are driving the colorectal cancer market growth.

On the contrary, pricing pressure on drug manufacturers hurdles the growth of North America colorectal cancer market.

The North America colorectal cancer market, based on modality, has been segmented into diagnosis type, therapy type, and imaging type. The diagnosis type segment held the largest share of the market of 42.6% market share in 2022, amassing US$ 3,646.33 million. It is projected to garner US$ 5,006.97 million by 2028 to expand at 4.0% CAGR during 2022–2028.

By the end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. With 62.4% share of the domain, the hospitals segment dominated the market in 2022. It accrued US$ 5,336.84 million in 2022 and is estimated to generate US$ 7,157.90 million by 2028 to grow at a CAGR of 3.7% over the forecast period.

Our regional analysis states that US captured 69.8% market share in 2022. It was assessed at US$ 5,978.12 million in 2022 and is likely to hit US$ 7,909.03 million by 2028, exhibiting a CAGR of 3.6% during the forecast period.

Key players dominating the North America colorectal cancer market are Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx among others.

In April 2022, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging (MRI) systems portfolio. Following the success of its BioSpec Maxwell 3 Tesla model, the new range of Maxwell 7 Tesla and 9.4 Tesla magnets eliminates the need for liquid Helium or Nitrogen refills, while offering high-field sensitivity and resolution for advanced preclinical MRI and PET/MR research.

In June 2021, Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for minimal residual disease (“MRD”) and recurrence monitoring of colorectal cancer (“CRC”), announced that three abstracts were presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, which took place virtually from June 4-8, 2021. The studies presented further validate the clinical benefit of our approach. Ongoing studies and monitoring have enabled us to further refine COLVERA analysis. With these improvements, COLVERA differentiates more accurately between patients with and without recurrent disease, and thus is clinically more informative. Contact Us

Contact Person: Sameer Joshi

Phone: +1- 646- 491- 9876

Email id: [email protected]

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Colorectal Cancer Market – By Modality

1.3.2 North America Colorectal Cancer Market – By End User

1.3.3 North America Colorectal Cancer Market – By Country

2. North America Colorectal Cancer Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Colorectal Cancer– Market Landscape

4.1 Overview

4.2 North America PEST Analysis

4.3 Expert Opinion

5. North America Colorectal Cancer Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Colorectal Cancer

5.1.2 New Product Launches

5.1.3 Benefits Offered by Generic Drugs

5.2 Market Restraints

5.2.1 Pricing Pressure on Drug Manufacturers

5.3 Future Trends

5.3.1 Inclination Toward Personalized Medicine

5.4 Impact Analysis

6. North America Colorectal Cancer Market– North America Analysis

6.1 North America Colorectal Cancer Market Revenue Forecast and Analysis

6.1.1 Overview

7. North America Colorectal Cancer Market Analysis – By Modality

7.1 Overview

7.2 North America Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)

7.3 Diagnosis Type

7.3.1 Overview

7.3.2 Diagnosis Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.3 Immunohistochemistry

7.3.3.1 Overview

7.3.3.2 Immunohistochemistry: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.4 Stool Test

7.3.4.1 Overview

7.3.4.2 Stool Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.5 Flexible Sigmoidoscopy

7.3.5.1 Overview

7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.6 Colonoscopy

7.3.6.1 Overview

7.3.6.2 Colonoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.7 CEA Test

7.3.7.1 Overview

7.3.7.2 CEA Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.3.8 Other Test

7.3.8.1 Overview

7.3.8.2 Other Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Therapy Type

7.4.1 Overview

7.4.2 North America Therapy Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3 Chemotherapy

7.4.3.1 Overview

7.4.3.2 Chemotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.3 Alkylating Agent

7.4.3.3.2 Overview

7.4.3.3.3 Alkylating Agent: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.4 Antimetabolites

7.4.3.4.2 Antimetabolites: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.3.5 Others

7.4.3.5.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4 Immunotherapy

7.4.4.1 Overview

7.4.4.2 Immunotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.3 Panitumumab

7.4.4.3.2 Overview

7.4.4.3.3 Panitumumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.4 Cetuximab

7.4.4.4.2 Overview

7.4.4.4.3 Cetuximab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.5 Bevacizumab

7.4.4.5.2 Overview

7.4.4.5.3 Bevacizumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.4.6 Others

7.4.4.6.2 Overview

7.4.4.6.3 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.5 Chemoprotectant

7.4.5.1 Overview

7.4.5.2 Chemoprotectant: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.4.6 Others

7.4.6.1 Overview

7.4.6.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Imaging Type

7.5.1 Overview

7.5.2 North America Imaging Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.3 Computed Tomography (CT)

7.5.3.1 Overview

7.5.3.2 Computed Tomography (CT): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.4 Magnetic Resonance Imaging (MRI)

7.5.4.1 Overview

7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

7.5.5 Others

7.5.5.1 Overview

7.5.5.2 Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

8. North America Colorectal Cancer Market Revenue and Forecast To 2028 – By End User

8.1 Overview

8.2 North America Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)

8.3 Hospitals

8.3.1 Overview

8.3.2 Hospitals: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Diagnostic and Research Laboratories

8.4.1 Overview

8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Colorectal Cancer Market Revenue and Forecast to 2028 – Country Analysis

9.1 North America: Colorectal Cancer Market

9.1.1 Overview

9.1.2 North America: Colorectal Cancer Market, by Country, 2022 & 2028 (%)

9.1.2.1 US: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

9.1.2.1.2 US: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

9.1.2.1.3 US: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.2.1.3.1 US: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.2.1.3.2 US: Colorectal Cancer Market, by Therapy Type– 2019- 2028 (US$ Million)

9.1.2.1.3.2.1 US: Colorectal Cancer Market, by Chemotherapy– 2019-2028 (US$ Million)

9.1.2.1.3.2.2 US: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.2.1.3.3 US: Colorectal Cancer Market, by Imaging Type – 2019–2028 (US$ Million)

9.1.2.1.4 US: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

9.1.2.2 Canada: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

9.1.2.2.2 Canada: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

9.1.2.2.3 Canada: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.2.2.3.1 Canada: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.2.2.3.1.1 Canada: Colorectal Cancer Market, by Therapy Type – 2019- 2028 (US$ Million)

9.1.2.2.3.1.2 Canada: Colorectal Cancer Market, by Chemotherapy– 2019-2028 (US$ Million)

9.1.2.2.3.2 Canada: Colorectal Cancer Market, by Imaging Type – 2019–2028 (US$ Million)

9.1.2.2.4 Canada: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

9.1.2.3 Mexico: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

9.1.2.3.2 Mexico: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

9.1.2.3.3 Mexico: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

9.1.2.3.3.1 Mexico: Colorectal Cancer Market, by Diagnosis Type – 2019–2028 (US$ Million)

9.1.2.3.3.2 Mexico: Colorectal Cancer Market, by Therapy Type – 2019- 2028 (US$ Million)

9.1.2.3.3.2.1 Mexico: Colorectal Cancer Market, by Chemotherapy– 2019-2028 (US$ Million)

9.1.2.3.3.2.2 Mexico: Colorectal Cancer Market, by Immunotherapy– 2019- 2028 (US$ Million)

9.1.2.3.3.3 Mexico: Colorectal Cancer Market, by Imaging Type – 2019–2028 (US$ Million)

9.1.2.3.4 Mexico: Colorectal Cancer Market - Revenue and Forecast To 2028, By End Users (US$ Million)

10. Colorectal Cancer Market – Industry Landscape

10.1 Overview

10.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028

10.3 Organic Developments

10.3.1 Overview

10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028

10.4 Inorganic Developments

10.4.1 Overview

10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028

11. Company Profiles

11.1 Epigenomics AG

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Clinical Genomics Technologies Pty. Ltd.

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Abbott

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Amgen Inc.

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 F. HOFFMANN-LA ROCHE LTD.

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Bruker Corporation

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 Quest Diagnostics Incorporated

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 Volitionrx Limited

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms

LIST OF TABLES.

Table 1.             US: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

Table 2.             US: Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             US: Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 4.             US: Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US: Colorectal Cancer Market, by Immunotherapy– Revenue and Forecast To 2028 (US$ Million)

Table 6.             US: Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 7.             US: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

Table 8.             Canada: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

Table 9.             Canada: Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Canada: Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Canada: Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Canada: Colorectal Cancer Market, by Immunotherapy– Revenue and Forecast To 2028 (US$ Million)

Table 13.          Canada: Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Canada: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

Table 15.          Mexico: Colorectal Cancer Market – Revenue and Forecast to 2028, By Modality (US$ Million)

Table 16.          Mexico: Colorectal Cancer Market, by Diagnosis Type – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Mexico: Colorectal Cancer Market, by Therapy Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Mexico: Colorectal Cancer Market, by Chemotherapy – Revenue and Forecast to 2028 (US$ Million)

Table 19.          Mexico: Colorectal Cancer Market, by Immunotherapy– Revenue and Forecast To 2028 (US$ Million)

Table 20.          Mexico: Colorectal Cancer Market, by Imaging Type – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Mexico: Colorectal Cancer Market - Revenue and Forecast To 2028, By End Users (US$ Million)

Table 22.          Recent Organic Growth Strategies In The Colorectal Cancer Market

Table 23.          Recent Inorganic Growth Strategies In The Colorectal Cancer Market

Table 24.          Glossary of Terms, North America Colorectal Cancer Market

LIST OF FIGURES.

Figure 1.           North America Colorectal Cancer Market Segmentation

Figure 2.           North America Colorectal Cancer Segmentation, By Country

Figure 3.           North America Colorectal Cancer Market Overview

Figure 4.           Diagnosis Type Segment Held Largest Share Of Modality Segment In North America Colorectal Cancer Market

Figure 5.           US is Expected To Show Remarkable Growth During The Forecast Period

Figure 6.           North America Colorectal Cancer Market - PEST Analysis

Figure 7.           Comparison of Branded Drugs and Generic Drugs

Figure 8.           North America Colorectal Cancer Market Impact Analysis of Drivers And Restraints

Figure 9.           North America Colorectal Cancer Market – Revenue Forecasts And Analysis – 2020- 2028

Figure 10.        North America Colorectal Cancer Market Revenue Share, by Modality 2022 & 2028 (%)

Figure 11.        North America Diagnosis Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        North America Immunohistochemistry: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        North America Stool Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        North America Flexible Sigmoidoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        North America Colonoscopy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        North America CEA Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        North America Other Test: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        North America Therapy Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        North America Chemotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Alkylating Agent: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        North America Antimetabolites: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        North America Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        North America Immunotherapy: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        North America Panitumumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        North America Cetuximab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        North America Bevacizumab: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        North America Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        North America Chemoprotectant: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        North America Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        North America Imaging Type: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        North America Computed Tomography (CT): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        North America Magnetic Resonance Imaging (MRI): Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.        North America Others: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        North America Colorectal Cancer Market Revenue Share, by End User 2022 & 2028 (%)

Figure 35.        North America Hospitals: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        North America Diagnostic and Research Laboratories: Colorectal Cancer Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        North America: Colorectal Cancer Market Revenue Overview, By Key Country – Revenue (2022) (US$ Million)

Figure 38.        North America: Colorectal Cancer Market, By Country, 2022 & 2028 (%)

Figure 39.        US: Colorectal Cancer Market Revenue and Forecast To 2028 (US$ Million)

Figure 40.        Canada: Colorectal Cancer Market Revenue and Forecast To 2028 (US$ Million)

Figure 41.        Mexico: Colorectal Cancer Market Revenue and Forecast To 2028 (US$ Million)

Figure 42.        Growth Strategies In The Colorectal Cancer Market, 2022-2028

The List of Companies - North America Colorectal Cancer Market

● Abbott

● Amgen Inc.

● Bruker Corporation

● Clinical Genomics Technologies Pty Ltd.

● Epigenomics AG

● F. Hoffmann-La Roche AG

● Quest Diagnostics  

● VolitionRx Limited

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America colorectal cancer market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the North America colorectal cancer market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the colorectal cancer market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP